Pharma BD Deal Intelligence

Labcorp / Myriad Genetics

2026 · Asset Purchase · $210M · Pending

Myriad Genetics entered a definitive agreement to sell its Prenatal Health testing business to Labcorp for USD 210 million in cash plus the value of the business's inventory at closing. The divested portfolio comprises the Prequel prenatal screen, the Foresight carrier screen, SneakPeek and FirstGene. Labcorp expects the acquired business to contribute approximately USD 160 million of revenue in year one, to be slightly accretive to adjusted earnings in year one, and to reach average Diagnostics-segment margins by the end of year two once integrated. Myriad positions the divestiture as strengthening its balance sheet and concentrating investment on its hereditary-cancer and oncology priorities. The transaction is expected to close in early 2027 and positions Labcorp against Natera, BillionToOne and Quest Diagnostics in prenatal screening.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Labcorp deals